Targeted Temperature Management & Post-Cardiac Arrest Care
Key Takeaways
Adults unresponsive to verbal commands after ROSC need a deliberate temperature-control strategy targeting 32–37.5 °C; at least 36 hours of total temperature control is reasonable.
Once reliable measurements are available, the 2025 AHA algorithm targets SpO2 90–98%, PaO2 60–105 mm Hg, and PaCO2 35–45 mm Hg.
Maintain MAP at least 65 mm Hg and individualize further support to organ perfusion and shock physiology.
TTM2 did not show superiority of 33 °C over controlled normothermia and reported more hemodynamically important arrhythmias with hypothermia.
Temperature and Physiology After Cardiac Arrest
The First Assessment After ROSC
Post-cardiac arrest syndrome includes brain injury, myocardial dysfunction, systemic ischemia–reperfusion effects, and the disease that caused the arrest. A pulse does not complete resuscitation. Confirm airway and ventilation, obtain reliable oxygenation and blood pressure measurements, record a twelve-lead ECG, and evaluate for coronary occlusion, pulmonary embolism, hemorrhage, toxic exposure, or another cause. Emergency coronary intervention depends on the ECG and clinical instability; it is not an automatic immediate procedure for every stable patient without ST elevation.
Treat hypotension and impaired perfusion while defining the shock phenotype. Assess rhythm, bedside cardiac function, volume responsiveness, lactate trend, urine output, and examination. The 2025 AHA approach maintains MAP at least 65 mm Hg. Some patients need an individualized higher goal, but a history of hypertension does not automatically prove that MAP 66 is inadequate or mandate 80–100. Choose fluids, vasopressors, and inotropes according to vasodilation, ventricular function, congestion, and response. Prevent recurrent arrest during transport and procedures.
Oxygenation and Ventilation
Use 100% inspired oxygen initially until oxygenation can be measured reliably. Once dependable saturation or arterial measurements are available, titrate oxygen to avoid both hypoxemia and unnecessary hyperoxemia. The 2025 AHA adult algorithm uses SpO2 90–98% and PaO2 60–105 mm Hg. Pulse oximetry may be inaccurate during low perfusion or with other measurement limitations; check the signal and use arterial gases when needed. Do not abruptly reduce oxygen on the basis of an unreliable display.
Target PaCO2 35–45 mm Hg in most comatose adults. Hypocapnia can reduce cerebral blood flow; uncontrolled hypercapnia can increase cerebral blood volume and worsen intracranial pressure. End-tidal CO2 is useful for trends but may diverge substantially from PaCO2 after arrest because of dead space and circulatory failure. Obtain gases after meaningful ventilator changes and use lung-protective ventilation adjusted to the patient. Avoid treating a low end-tidal value as proof that arterial CO2 must also be low.
For example, PaO2 285 and PaCO2 28 on FiO2 1.0 suggest excessive oxygen exposure and ventilation once measurements are reliable. Gradually reduce FiO2 and minute ventilation toward the supported ranges while monitoring oxygenation and repeat gases. MAP 66 meets the guideline minimum, but still warrants evaluation of the actual perfusion state; it does not independently mandate a particular pressor dose.
Temperature Strategy and Evidence
Adults unresponsive to verbal commands after ROSC should receive a deliberate temperature-control strategy with a selected temperature between 32 and 37.5 °C. At least 36 hours of total temperature control is reasonable in this group. This is not necessarily 36 hours at one hypothermic target followed by a separately mandated additional 72-hour phase. Plan ongoing fever surveillance and prevention according to the clinical course and protocol. Avoid rapid active rewarming of a spontaneously hypothermic patient.
Early hypothermia trials in selected shockable out-of-hospital arrests supported improved neurologic outcomes, but differed in enrollment, cooling duration, and outcome timing. They should not be summarized as identical trials with the same mortality result. TTM1 did not demonstrate a significant outcome difference between targets of 33 and 36 °C. HYPERION reported a modest favorable neurologic outcome signal in nonshockable arrests without a significant mortality reduction; later evidence and population differences limit broad extrapolation.
TTM2, led by Dankiewicz and colleagues, compared 33 °C with normothermia and early fever treatment after out-of-hospital arrest. Six-month mortality was 50% versus 48%, without a significant difference; moderately severe disability or worse, measured by mRS at least 4, occurred in 55% of both groups. Hemodynamically compromising arrhythmias were more frequent with hypothermia, 24% versus 17%. A neutral superiority trial does not prove exact equivalence or exclude every possible subgroup effect. It supports selecting a controlled strategy without claiming universal superiority of 33 °C.
Deliver Control Safely
Use a reliable core temperature site and a protocol appropriate to surface or intravascular devices. Check skin, access sites, device function, and infection risk. Large rapid cold crystalloid infusions are not a routine post-arrest cooling strategy. Monitor potassium and other electrolytes, glucose, rhythm, coagulation, and drug accumulation during cooling and rewarming. Hypothermia can prolong sedative effects, which must be considered later in prognostication.
Shivering increases metabolic demand and can prevent temperature control. Assess it by examination, palpation, and a consistent bedside scale. Begin with appropriate skin counter-warming and analgesia, then use protocol-based medication while considering organ function, interactions, and hemodynamics. Acetaminophen dosing depends on liver function and total exposure; magnesium requires renal and level monitoring. Buspirone and other agents are protocol options rather than a mandatory fixed-dose bundle. Meperidine's neurotoxic metabolite is a particular concern with renal impairment.
If deep sedation or neuromuscular blockade is necessary for refractory shivering, provide adequate analgesia and hypnosis before paralysis. Paralysis hides convulsions and bedside motor responses; EEG monitoring is particularly important when seizures are suspected or examination is unavailable. Use the minimum effective blockade and reassess. Continue seizure assessment, nutrition, thromboprophylaxis, infection evaluation, and family communication. Temperature management does not establish prognosis, and early coma or myoclonus alone does not establish futility.
Source: 2025 AHA adult post-arrest care algorithm and TTM2 trial.
Decision Review
| Parameter | 2025 AHA adult approach |
|---|---|
| Oxygen after reliable measurement | SpO2 90–98% and PaO2 60–105 mm Hg |
| Ventilation | PaCO2 35–45 mm Hg in most comatose adults |
| Pressure | MAP at least 65 mm Hg, with further support individualized |
| Temperature | Deliberate target 32–37.5 °C; at least 36 hours of total control reasonable |
Which strategy fits the 2025 AHA adult post-arrest temperature guidance?
Every patient must receive 28 °C for twelve hours
A deliberate target within 32–37.5 °C, with at least 36 hours of total temperature control reasonable
Stop monitoring after the first normal temperature
Rapidly warm every spontaneously hypothermic patient
Reliable gases after ROSC show PaO2 285 and PaCO2 28. Which change is appropriate?
Increase ventilation to reduce CO2 further
Keep FiO2 1.0 indefinitely
Titrate oxygen and ventilation toward SpO2 90–98%, PaO2 60–105, and PaCO2 35–45 while reassessing perfusion
Lower MAP to 55 to reduce cardiac workload
What does TTM2 support?
Exact equivalence in every possible arrest subgroup
A mortality advantage from cooling to 33 °C
Abandonment of temperature monitoring
No significant superiority of 33 °C over controlled normothermia in the enrolled population, with more important arrhythmias in the hypothermia arm
Sections you finish are checked off in the contents.